Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels
Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels
复制标题
DOI：
10.3748/wjg.v16.i32.4095
复制
发表时间：
2010-08-28
影响因子：
4.3
通讯作者：
Yang, Yi-Da
中科院分区：
文献类型：
--
作者：
Lv, Guo-Cai;Ma, Wen-Jiang;Yang, Yi-Da
目的：评价替比夫定（LDT）治疗基线丙氨酸氨基转移酶（ALT）水平高于正常上限10 - 20倍的B e抗原（HBeAg）阳性慢性B肝炎（CH B）患者的疗效和安全性。40例HBeAg-入选基线ALT水平在正常上限10 - 20倍之间的高基线ALT水平的阳性CHB患者，并接受LDT单药治疗，52周另外40例基线ALT水平为正常上限2 - 10倍的患者作为对照。结果：治疗52周时，ALT升高组和对照组的HBV DNA水平分别较治疗前下降7.03 log 10 copies/mL和6.17 log 10 copies/mL（P
AIM: To evaluate the efficacy and safety of telbivudine (LDT) in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients who have high baseline alanine aminotransferase (ALT) levels between 10 and 20 times the upper limit of normal.METHODS: Forty HBeAg-positive CHB patients with high baseline ALT levels between 10 and 20 times the upper limit of normal were enrolled and received LDT monotherapy for 52 wk. Another forty patients with baseline ALT levels between 2 and 10 times the upper limit of normal were included as controls. We compared the virological, biochemical, serological and side effect profiles between the two groups at 52 wk.RESULTS: By week 52, the mean decrease in hepatitis B virus (HBV) DNA level compared with baseline was 7.03 log10 copies/mL in the high baseline ALT group and 6.17 log10 copies/mL in the control group, respectively (P